WallStSmart

Insmed Inc (INSM)vsOrchestra BioMed Holdings Inc. (OBIO)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Insmed Inc generates 1711% more annual revenue ($606.42M vs $33.48M). OBIO leads profitability with a -1.6% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).

INSM

Hold

39

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 6.7Quality: 6.3
Piotroski: 6/9Altman Z: -3.77

OBIO

Avoid

32

out of 100

Grade: F

Growth: 8.0Profit: 3.5Value: 5.0Quality: 6.5
Piotroski: 3/9Altman Z: -6.21

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

INSM0 strengths · Avg: 0/10

No standout strengths identified

OBIO3 strengths · Avg: 9.3/10
Revenue GrowthGrowth
121.2%10/10

Revenue surging 121.2% year-over-year

Debt/EquityHealth
0.0410/10

Conservative balance sheet, low leverage

Operating MarginProfitability
21.8%8/10

Strong operational efficiency at 21.8%

Areas to Watch

INSM4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
1.5%4/10

1.5% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Price/BookValuation
43.0x2/10

Trading at 43.0x book value

Return on EquityProfitability
-2.5%2/10

ROE of -2.5% — below average capital efficiency

OBIO4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$278.56M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-109.4%2/10

ROE of -109.4% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : INSM

PEG of 1.09 suggests the stock is reasonably priced for its growth.

Bull Case : OBIO

The strongest argument for OBIO centers on Revenue Growth, Debt/Equity, Operating Margin. Revenue growth of 121.2% demonstrates continued momentum.

Bear Case : INSM

The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.

Bear Case : OBIO

The primary concerns for OBIO are EPS Growth, Market Cap, Piotroski F-Score.

Key Dynamics to Monitor

INSM profiles as a turnaround stock while OBIO is a hypergrowth play — different risk/reward profiles.

INSM carries more volatility with a beta of 1.17 — expect wider price swings.

OBIO is growing revenue faster at 121.2% — sustainability is the question.

OBIO generates stronger free cash flow (-2M), providing more financial flexibility.

Bottom Line

INSM scores higher overall (39/100 vs 32/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Insmed Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.

Orchestra BioMed Holdings Inc.

HEALTHCARE · BIOTECHNOLOGY · USA

Orchestra BioMed Holdings, Inc. is a therapeutic device company that develops therapeutic treatments and products for cardiovascular diseases. The company is headquartered in New Hope, Pennsylvania.

Want to dig deeper into these stocks?